Crossmark

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia

Crossref DOI link: https://doi.org/10.1186/s40425-019-0509-0

Published Online: 2019-01-29

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bagacean, Cristina https://orcid.org/0000-0001-6061-992X
Tempescul, Adrian

Ternant, David

Banet, Anne

Douet-Guilbert, Nathalie

Bordron, Anne

Bendaoud, Boutahar

Saad, Hussam

Zdrenghea, Mihnea

Berthou, Christian

Paintaud, Gilles

Renaudineau, Yves
More Information

Article History

Received: 2 November 2018

Accepted: 13 January 2019

First Online: 29 January 2019

Ethics approval and consent to participate

: Consent was obtained from all individuals and the protocol approved by the Ethical Board (: NCT03294980; CRB Brest, collection 2008–214), in accordance with the Declaration of Helsinki.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.